Last reviewed · How we verify
Fiasp®
Fiasp® is a Rapid-acting insulin analog Small molecule drug developed by Novo Nordisk A/S. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: Fast Acting Insulin Aspart.
Fiasp is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.
Fiasp is a medication used to treat conditions related to glucose metabolism disorders, including diabetes mellitus and type 1 diabetes mellitus. It works as an insulin receptor agonist, a type of protein that activates the insulin receptor.
At a glance
| Generic name | Fiasp® |
|---|---|
| Also known as | Fast Acting Insulin Aspart |
| Sponsor | Novo Nordisk A/S |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Fiasp (insulin aspart) is a mealtime insulin that mimics the body's natural rapid insulin secretion in response to meals. It contains two excipients (niacinamide and L-arginine) that accelerate absorption from the subcutaneous injection site, allowing faster onset and earlier peak action compared to standard insulin aspart. This enables improved postprandial glucose control in patients with diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Headache
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
- Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (PHASE2)
- Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid® (PHASE1)
- A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
- A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes (PHASE1)
- Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes (PHASE3)
- Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fiasp® CI brief — competitive landscape report
- Fiasp® updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about Fiasp®
What is Fiasp®?
How does Fiasp® work?
What is Fiasp® used for?
Who makes Fiasp®?
Is Fiasp® also known as anything else?
What drug class is Fiasp® in?
What development phase is Fiasp® in?
What are the side effects of Fiasp®?
What does Fiasp® target?
Related
- Drug class: All Rapid-acting insulin analog drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Novo Nordisk A/S — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Fast Acting Insulin Aspart
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing